Expertise in
1
conditions

Jiankang Hu

P.R. China, 
Pingxiang, CN 
Expertise in
1
conditions
P.R. China, 
Pingxiang, CN 

Overview

Jiankang Hu practices practicing medicine in Pingxiang, China.

Hu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Gout, Axial Spondyloarthritis (AxSpA), Arthritis, and Rheumatoid Arthritis (RA).

They are actively involved in clinical research, co-authoring 28 peer reviewed articles and participating in 5 clinical trials.

Locations

P.R. China, Pingxiang, China
Other Locations
Xiangtan, 411105, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: March 27, 2024
Intervention Type: Biological, Drug
Study Drugs: GSK3196165, Tofacitinib, Methotrexate, Folic acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Enrollment Status: Terminated
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
A Multicenter, Randomized, Double-Blind and Placebo-Controlled 16-Week Study Followed by Long Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Chinese Patients With Radiographic Axial Spondyloarthritis
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drug: Ixekizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus
Enrollment Status: Terminated
Publish Date: January 30, 2023
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
Enrollment Status: Terminated
Publish Date: June 21, 2022
Intervention Type: Drug, Other
Study Drug: Hemay005
Study Phase: Phase 2
View 4 Less Clinical Trials

28 Total Publications

High baseline neutrophil-to-lymphocyte ratio is associated with better adalimumab response in patients with rheumatoid arthritis.
High baseline neutrophil-to-lymphocyte ratio is associated with better adalimumab response in patients with rheumatoid arthritis.
Journal: The Journal of international medical research
Published: June 18, 2026

Frequently Asked Questions about Jiankang Hu

Is Jiankang Hu a top-rated expert for Gout?

MediFind is an objective health platform that identifies experts based on real-world data. Jiankang Hu is classified as an Advanced expert for Gout, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jiankang Hu participate in research or clinical trials?

Yes. Jiankang Hu has published 28 articles and abstracts on conditions like Gout. You can view a list of Jiankang Hu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hu's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile